NDAORALTABLET
Approved
May 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ZESTRIL (lisinopril) by Lavipharm is angiotensin-converting enzyme (ace) in human subjects and animals. First approved in 1988.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZESTRIL (lisinopril) is an oral ACE inhibitor approved in 1988 for hypertension and heart failure. It works by suppressing the renin-angiotensin-aldosterone system, reducing angiotensin II and aldosterone to lower blood pressure and improve cardiac function. The drug is effective across racial groups, though Black patients may require combination therapy for optimal response.
$0.004BPart D
LOE ApproachingStable
Product is in LOE phase with modest Part D utilization (~3,500 claims), indicating a mature franchise with limited growth opportunities for brand teams.
Mechanism of Action
angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of…
Indications
Worked on ZESTRIL at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.